artifical panc.JPG

 

APDS.JPG

SUMMARY

  • FDA is helping advance the development of an artificial pancreas device system (APDS)—an innovative device that automatically monitors blood glucose and provides appropriate insulin doses in people with diabetes who use insulin
  • Forward looking Guidance issued – prior to any approved device – to encourage development
  • Recommendations on appropriate endpoints and evidentiary standards for PMA approval; pediatric development encouraged
  • Manufacturers need to also focus on Quality System: Software (including sensors) and Hardware. Software problems anticipated. Require design features to prevent malfunctioning of system.
  • Cybersecurity concerns need to be addressed.
  • Interoperability issues need to be addressed
  • Regulatory burden for new technology depends on scope
  • Encourage Pre-Submission Meeting to align on required studies and study design to meet Intended Use/Indication for Use. Identify patient population, appropriate software algorithm for dosing for designing trial
  • Medtronic has completed pivotal trial with APDS and FDA submission anticipated

RESOURCES

Pancrea1

 

Guidance

pabcrea2

Website

 

 

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s